Diagonal Bio AB (publ) (DIABIO.ST) Research

Diagonal Bio AB is a Swedish biotechnology firm dedicated to advancing the Panviral platform. This innovative technology is engineered to pinpoint and diagnose minute genetic fragments belonging to a range of pathogens, such as viruses, bacteria, and fungi. Established in 2020, the company's main operations are based in Lund, Sweden.

Market snapshot

Symbol
DIABIO.ST
Price
$0.01
Day change
0.00%
Market cap
$20.2M
P/E ratio
-2.52x
52-week range
0.012-0.016
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • AegirBio AB (publ) (AEGIR.ST)
  • Amniotics AB (publ) (AMNI.ST)
  • Cyxone AB (publ) (CYXO.ST)
  • Idogen AB (publ) (IDOGEN.ST)
  • Learning 2 Sleep L2S AB (publ) (L2S.ST)
  • Pharmiva AB (publ) (PHARM.ST)
  • Pharmacolog i Uppsala AB (publ) (PHLOG-B.ST)
  • Redwood Pharma AB (REDW.ST)

Open Diagonal Bio AB (publ) (DIABIO.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.